Connecticut officials are demanding that Alexion return the 26-million-dollars the state provided the company to relocate to New Haven.
Alexion announced yesterday that it plans to relocate their headquarters from New Haven to Boston, and says they will pay the state back.
The rare disease drug maker plans to leave 450 employees behind in Connecticut and move 400 others to Boston by next year.
The New Haven headquarters that opened last year will become a research and development facility.